Volume 1, Issue 3, Pages (April 2002)

Slides:



Advertisements
Similar presentations
Chemical Genomics – Biol503 Lecture 2 Chemical Genomics and cancer/cardiovascular diseases.
Advertisements

Introduction The effects of HER2 gene and receptor over- expression on breast cancer. Prognosis and treatment of HER2+ breast cancer. (See figure 1)
Functional interactions between calmodulin and estrogen receptor-α
Negative regulation of cell cycle by intracellular signals Checkpoint p53 detects DNA damage & activates p21 p21 inhibits cdk2-cyclinA Intracellular Regulation.
An Introduction to Medicinal Chemistry 3/e PROTEINS AS DRUG TARGETS:
Epidermal growth factor receptor tyrosine kinase inhibitors as initial therapy for non- small cell lung cancer: Focus on epidermal growth factor receptor.
Estrogen & Estrogen Receptor
Figure 1. Resistance mechanism against first generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI). (A) Mutations in the EGFR.
Cell Communication.
Inflammation and Cancer: IL-6 and STAT3 Complete the Link
Overview of Cellular Signaling Mechanisms
SIGNAL TRANSDUCTION Signal Transduction Pathway Protein Modification Phosphorylation Cascade Protein Kinases.
Charles Swanton, Julian Downward  Cancer Cell 
Cell Communication.
A Nurr1 Pathway for Neuroprotection
Cancer and Cell Communication
Cell Communication.
Volume 100, Issue 1, Pages (January 2000)
HER2/HER3 heterodimers in prostate cancer
Trachealess—A New Transcription Factor Target for PKB/Akt
Cell Communication.
Cell Communication (1.4) – Part 1
c-Kit as a Novel Potential Therapeutic Target in Colorectal Cancer
Cell to Cell Communication via Enzyme Linked Receptors
Ulipristal acetate for the management of large uterine fibroids associated with heavy bleeding: a review  Jacques Donnez, Guillaume E. Courtoy, Olivier.
Figure 4 Possible combination therapies CDK4/6 inhibitors
Dan Gordon  Gastroenterology  Volume 114, Issue 4, (April 1998)
A Sweet New Role for EGFR in Cancer
Figure 2 Oestrogen receptor signalling pathways
Cell Walls: Monitoring Integrity with THE Kinase
Integrins and Mutant p53 on the Road to Metastasis
Integrins and Mutant p53 on the Road to Metastasis
Selective estrogen receptor modulation
Cell Communication.
Uncovering a Tumor Suppressor for Triple-Negative Breast Cancers
EGFR T790M Mutation: A Double Role in Lung Cancer Cell Survival?
A genome-based strategy uncovers frequent BRAF mutations in melanoma
Inflammation, Epithelial to Mesenchymal Transition, and Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Resistance  Kostyantyn Krysan, PhD,
Apoptosis-targeted therapies for cancer
A. Craig Lockhart, Mace L. Rothenberg, Jordan D. Berlin 
Volume 22, Issue 6, Pages (December 2012)
An Invitation to T and More
Estrogen Receptor (ER) and Epidermal Growth Factor Receptor (EGFR) as Targets for Dual Lung Cancer Therapy: Not Just a Case?  Monica Giovannini, MD, Carmen.
Taru Muranen, Funda Meric-Bernstam, Gordon B. Mills  Cancer Cell 
Cell Communication.
Vascular Endothelial Growth Factor (VEGF) Pathway
Cell Communication.
Neil J. McKenna, Bert W. O'Malley  Cell 
Trachealess—A New Transcription Factor Target for PKB/Akt
Targeting Smads to Restore Transforming Growth Factor-β Signaling and Regulatory T- Cell Function in Inflammatory Bowel Disease  Deanna D. Nguyen, Scott.
Signal Transduction: RABGEF1 Fingers RAS for Ubiquitination
Vascular Endothelial Growth Factor and Epidermal Growth Factor Signaling Pathways as Therapeutic Targets for Colorectal Cancer  Thomas Winder, Heinz–Josef.
The RAS/MAPK Axis Gets Stressed Out
RAS and PD-L1: A Masters’ Liaison in Cancer Immune Evasion
SRC and STAT Pathways Journal of Thoracic Oncology
Conspiracy Theory Cell
Apoptosis-targeted therapies for cancer
Fibronectin at Select Sites Binds Multiple Growth Factors and Enhances their Activity: Expansion of the Collaborative ECM-GF Paradigm  Jia Zhu, Richard.
The Expanding Cosmos of Nuclear Receptor Coactivators
Ethylene Prunes Translation
Insider Influence on ErbB Activity
The Thyroid and Metabolism: The Action Continues
Protein Tyrosine Phosphatase 1B
Chapter 11 A. Cell Signals Cell signaling has evolved over time
Transcriptional control of adipocyte formation
The new kid on the block(ade) of the IGF-1 receptor
Friends with Benefits: Microenvironmental NRG1β and HGF Mediate HER2-Targeted Resistance in L-HER2+ and HER2E Breast Cancer  Sarah B. Crist, Cyrus M.
Lesley-Ann Martin, Mitch Dowsett  Cancer Cell 
Volume 7, Issue 1, Pages 1-11 (July 1997)
Tackling Resistance to PI3K Inhibition by Targeting the Epigenome
Presentation transcript:

Volume 1, Issue 3, Pages 215-217 (April 2002) The secrets of selective estrogen receptor modulation: Cell-specific coregulation  V.Craig Jordan  Cancer Cell  Volume 1, Issue 3, Pages 215-217 (April 2002) DOI: 10.1016/S1535-6108(02)00050-8

Figure 1 Integrated mechanism for the target site specific action of SERMs in breast or uterine cancer The two extremes of antiestrogenic or full estrogenic actions are shown. Estrogen-like actions could occur in cells expressing an excess of coactivators (CoAs) and/or a decrease in corepressors (CoRs). The charged surface of a tamoxifen ER complex at AF2b prevents CoR binding. The estrogenic action would be amplified by surface signaling with dimers of epidermal growth factor receptor (EGFR) and HER2/neu activating tyrosine kinases (tks). The phosphorylation cascade can activate AF-1 on ERα directly or activate the excess of CoAs in a high ER environment. Reduced levels of ER prevent the signal transduction pathway and promote antiestrogenic actions in a surface silent cell. Cancer Cell 2002 1, 215-217DOI: (10.1016/S1535-6108(02)00050-8)